Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2026
Can-Fite receives Eurasian patent allowance for Piclidenoson use in Lowe syndrome
Can-Fite announced that the Eurasian Patent Office issued a notification of readiness to grant a patent covering Piclidenoson use for diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2. The grant remains subject to completion of required formalities.
2021
Can-Fite and Ewopharma sign exclusive distribution agreement
Can-Fite announced that it signed an exclusive distribution agreement with Ewopharma. Ewopharma will have exclusive rights to market and sell Piclidenoson in Central Eastern European countries and Namodenoson in Central Eastern European countries and Switzerland, in exchange for upfront and milestone payments and royalties.